396 results about "Molecular diagnostics" patented technology

The invention belongs to the technical field of organic synthesis, and particularly discloses an ammonia aromatic alkene modified near-infrared BODIPY fluorescent probe as well as a preparation method and application thereof.The near-infrared BODIPY fluorescent probe is obtained by adopting 6-(dimethylamino) nicotinic aldehyde to directionally modify the alpha position of BODIPY and constructing an expanded conjugated system through Knoevenagel condensation. Wherein dimethylamino provides a strong electron donating effect, a molecular structure is twisted into a non-planar configuration due to steric hindrance of a pyridine ring, pi-pi accumulation is reduced, and an ACQ effect is inhibited. According to the structural modification strategy, significant red shift of absorption / emission wavelength is realized by expanding a molecular pi-conjugated skeleton, and meanwhile, the stability of the BODIPY core and the quantum yield are effectively enhanced. The probe molecule can specifically recognize the diphenylalanine dipeptide structural unit by utilizing the synergistic coordination effect of the 2-aminopyridine derivative and the BODIPY mother nucleus, so that the selective detection of the Alzheimer's disease biomarker Abeta42 is realized, and a novel optical detection tool is provided for the early molecular diagnosis and targeted therapy of AD (Alzheimer's disease).

This disclosure relates to apparatus and methods for molecular diagnostics. Certain embodiments include a piston cycled from a first position proximal to a first end of a housing, to a second position proximal to a second end of the housing, and back to the first position proximal to the first end of the housing. In some embodiments, the present disclosure relates to devices, methods, and systems for molecular diagnostics that do not comprise a piston.

The present invention relates to the technical field of medical instruments, and relates to the technical field of small amplification devices, especially portable amplification devices. Disclosed are a pressing and sealing apparatus for a POCT kit, and a molecular diagnostic device and operation method. The pressing and sealing apparatus for a POCT kit comprises a movable bracket, wherein a transmission assembly can drive the movable bracket to enable a sealing portion to seal a reaction chamber of the POCT kit when the movable bracket moves in a first direction; and when the transmission assembly drives the movable bracket to move in a second direction, a pressing portion comes into contact with the reaction chamber of the POCT kit to enable the reaction chamber of the POCT kit to tightly fit with a heat source. In the molecular diagnostic device including the pressing and sealing apparatus, a valve control portion and a clamping device share a second drive motor, a hot-melt bonding portion of the sealing portion and a detection and acquisition unit of the pressing portion share a first drive motor, a gas source drive part and a clamping apparatus cooperate with each other to drive liquid to flow through chambers of the kit, thereby achieving high integration, few drive parts, reliable operation, high detection accuracy, and small contamination.

The present invention relates to a method for the ex vivo molecular diagnosis of gastrointestinal stromal tumors, comprising the steps of: providing at least one isolated tissue sample comprising at least one nucleic acid and the subsequent extraction of the at least one nucleic acid. The method according to the present invention further comprises a step of quantifying the at least one previously isolated nucleic acid. Furthermore, the method according to the present invention comprises preparing at least one amplicon library of said previously isolated nucleic acid, which comprises sequences obtained from the FGFR1, NF1, SDHA, SDHB, SDHC and SDHD genes. This step is followed by the step of purifying the at least one amplicon library and the step of simultaneously sequencing the amplicons themselves. The present invention also relates to a multi-gene panel for ex vivo molecular diagnosis of gastrointestinal stromal tumors and a kit comprising such a panel.

The invention relates to the technical field of crossing of biomedical engineering, molecular diagnosis and nano-optical sensing, and particularly discloses a virus nucleic acid variation amplification-free LSPR (Local Surface Plasmon Resonance) detection method and chip based on a gold nano-structure. The virus nucleic acid variation amplification-free LSPR detection chip based on the gold nanostructure comprises a sample injection port, a reaction area, a washing area, a detection area and a waste liquid area, the sample injection port is used for injecting a viral nucleic acid or protein sample, a plurality of groups of probe sequences are fixed in different reaction regions of the chip, non-amplification rapid detection of viral nucleic acid variation is realized, high sensitivity and specificity are ensured, and by utilizing the unique advantages of an MSNs template branched gold nanostructure, the detection sensitivity is improved. Refractive index change caused by single base mutation is directly amplified, the capability of completing femtomole-level detection within 30 minutes is achieved, the overall detection speed is increased, rapid typing detection of viral nucleic acid variation is achieved through LSPR spectral signals under the non-amplification condition, and a portable platform is formed by integrating the LSPR spectral signals and a micro-fluidic chip.

The invention relates to the technical field of biosensors, in particular to a novel thin film material for a molecular diagnosis nascent biosensor, a thin film transistor and a preparation method and application of the novel thin film material and the thin film transistor. The thin film transistor is prepared from a novel thin film material, the thin film material covers the surface of a substrate of the transistor, and a source electrode and a drain electrode of the transistor are arranged between the substrate and a thin film in parallel. The concentration of the cancer marker is detected by monitoring the variable quantity of threshold voltage (Vth) in a transfer curve of the organic-inorganic hybrid thin film transistor, the responsivity and sensitivity to a disease marker are improved by optimizing a semiconductor material combination, efficient detection of the low-concentration cancer marker is realized, and the method has the characteristics of no label, rapidness, simplicity and convenience, and is suitable for popularization and application. The kit is suitable for early diagnosis of diseases.

The invention belongs to the field of nucleic acid detection and molecular biology, and particularly relates to a method and a kit for eliminating false positive results in nucleic acid amplification reaction. According to the method, after a nucleic acid amplification reaction (taking recombinase polymerase amplification, namely RPA, for example) is completed, a target amplification product is subjected to selective enzyme digestion by utilizing restriction endonuclease, non-target products (such as primer dimers and non-specific amplification products) are not cut, and meanwhile, the non-target products which are not subjected to enzyme digestion are removed by combining solid-phase separation, so that the target amplification product is obtained. Therefore, the false positive result is eliminated. The invention also discloses a kit containing the restriction enzyme. According to the method, the specificity and the signal-to-noise ratio of a nucleic acid amplification reaction, especially RPA, are remarkably improved, the cost is low, operation is easy, the method is compatible with an existing technical platform, the method is suitable for detection scenes such as clinical molecular diagnosis, environmental monitoring and food safety, and the problem of misjudgment caused by false positive signals is effectively avoided.

The invention discloses a nucleic acid detection consumable processing module, a detection system and a use method, and belongs to the field of medical examination and inspection instruments and molecular diagnosis and detection instruments, the technical key points are that the nucleic acid detection consumable processing module comprises a driving module, a temperature control and clamping integrated module, an L-shaped consumable lifting bracket and a flip module; and the driving module is used for driving the temperature control and clamping integrated module to clamp / loosen a detection chip of the consumable, driving the L-shaped consumable lifting bracket to ascend / descend and driving the flip module to rotate at the same time. The invention aims to provide the nucleic acid detection consumable processing module, the detection system and the use method, and the operation of sample processing and detection is simplified.

The application discloses an exosome small non-coding RNA molecule marker and application thereof, and belongs to the field of tumor liquid biopsy and molecular diagnosis. The exosome small non-coding RNA molecule marker is at least one of tRNA-GlyGCC-5 and sRESE; the nucleotide sequence of the tRNA-GlyGCC-5 is shown as SEQ ID NO:1; and the nucleotide sequence of the sRESE is shown as SEQ ID NO:2. The sRESE in the application is a brand new small non-coding RNA sequence, and is first discovered by the inventor, which is important for the marker of esophageal cancer and the research on disease progression mechanism. The tumor diagnosis kit provided by the application, which comprises the exosome small non-coding RNA molecule marker, is a liquid diagnosis monitoring kit with non-invasiveness, high sensitivity, high specificity and applicability to general survey or screening.

The invention relates to the technical field of molecular diagnosis, and discloses a miRNA combination for assisting hepatic fibrosis staged screening, a kit and a use method, the miRNA combination comprises miR-216b-5p, miR-2681-5p, miR-1178-3p, miR-1323 and miR-4418, the kit is used for ddPCR detection of the content of miRNA markers in a sample, and the kit comprises a miRNA marker reverse transcription primer and a miRNA marker amplification primer. The miRNA composition provided by the invention is an ideal and reliable miRNA marker used for assisting in hepatic fibrosis staged screening, the reverse transcription primer and the amplification primer provided by the detection kit have good specificity, high sensitivity and strong specificity, and a more accurate and reliable miRNA marker concentration value can be obtained based on the ddPCR technology in combination with the kit provided by the invention.

The invention discloses a cryptosporidium infection early warning method based on pasture environment and oocyst detection rate analysis, which comprises the following steps: collecting pasture multi-medium environment samples and corresponding parameters, and acquiring oocyst concentration by adopting a real-time quantitative PCR (Polymerase Chain Reaction) and a molecular diagnosis model; analyzing association between the oocysts and environmental factors through an oocyst propagation and environmental dynamics model; a key environment variable weight is determined by using MaxEnt and GloWPa-Crypto algorithms, and an oocyst diffusion path is simulated; and fusing multi-dimensional data to divide risk levels, and outputting the infection risk value and duration of each region through iterative operation. According to the method, through multi-medium sampling, multi-model fusion and multi-data deep fusion, the defects of single data, inaccurate propagation process description and insufficient data fusion in the prior art are overcome, the actual infection risks of different areas of the pasture can be accurately reflected, and a precise basis is provided for prevention and control.

The invention belongs to the technical field of tumor molecular diagnosis and biological information analysis, and relates to a high-throughput sequencing method and system for monitoring acute lymphocytic leukemia (MRD). Through targeted sequencing with a unique molecular identifier and / or a double-chain tag, error modeling based on a background noise spectrum and statistics / machine learning pseudo variation filtering, ultra-deep accurate detection of IG / TCR cloning and related gene low-frequency variation is realized. And an artificial intelligence recurrence risk prediction model is established by combining a time sequence MRD index, cloning diversity and clinical information, and a structured clinical report is output and docked with LIS / HIS. According to the method, the sensitivity and the specificity of ALL minimal residual disease detection can be remarkably improved, dynamic evaluation on leukemia cloning evolution and recurrence risks is realized, and a reliable basis is provided for individualized treatment decision and long-term follow-up visit.

The disclosure provides compositions, methods, and systems for implementation of high-performance molecular diagnostic assays involving color combinatorics, stimulus-responsive probes, tandem probes, conjugated polymer probes, and other mechanisms for increasing the number of targets that can be simultaneously detected in a digital assay. Multiplexed detection of targets is achieved in a rapid manner, with respect to sample partitioning and target detection using multiple color channels for detection.

The invention belongs to the technical field of characterization of target analytes, and provides application of PANX2 protein and a mutant thereof as biopore protein. The bioporous protein is used for detecting one or more of metal ions, inorganic salts, amino acids, nucleotides, small molecule drugs, small molecule diagnostic agents, adenosine triphosphate and monosaccharides. After one or more amino acids of the wild type PANX2 protein are mutated into common amino acids except original amino acids, compared with the wild type PANX2 protein, the PANX2 protein mutant can be normally expressed and is stable in property, a current signal is obviously improved during detection, the up-down amplitude of the current signal is longer, and burrs are fewer.

The invention relates to the field of molecular diagnosis and nucleic acid amplification, in particular to a recombinase polymerization amplification method based on Twinkle helicase enhancement and application of the recombinase polymerization amplification method. According to the invention, Twinkle helicase is introduced into an RPA system for the first time, and primer combination and template unlinking are assisted by utilizing ATP-dependent unlinking activity and DNA annealing activity of the Twinkle helicase, so that the amplification efficiency and the detection sensitivity are remarkably improved. The method is suitable for plasmid DNA, a high GC template and a clinical nucleic acid sample, and can be used for constructing an RPA kit containing Twinkle, so that the application of the RPA kit in pathogen detection, molecular diagnosis and on-site rapid detection is expanded. According to the invention, the defects of the existing RPA technology in sensitivity and stability are overcome, and a new solution is provided for developing a novel nucleic acid self-detection and field detection tool.

The disclosure provides compositions, methods, and systems for implementation of highly multiplexed molecular diagnostic assays involving color combinatorics, stimulus-responsive probes, tandem probes, conjugated polymer probes, and other mechanisms for increasing the number of targets that can be simultaneously detected in a digital assay. Multiplexed detection of targets is achieved in a rapid manner, with respect to sample partitioning and target detection using multiple color channels for detection. Implementation of methods described also achieve detection with significantly improved signal-to-noise ratio (SNR) values.

The invention relates to the technical field of markers, in particular to application of a biomarker for identifying acute stage and chronic stage of brucellosis. A series of biomarkers related to acute and chronic stages of brucellosis are screened and found, and the biomarkers have obvious difference between acute and chronic brucellosis patients. The biomarkers can realize acute and chronic staging of brucellosis, are high in sensitivity and specificity, and have relatively good diagnosis efficiency. A novel molecular diagnosis tool is provided for acute and chronic staging of brucellosis, the problems that existing serological detection is low in specificity, and clinical staging cannot be accurately judged are solved, and wide application prospects are achieved.

A hand-held molecular diagnostic test device includes a housing, an amplification (or PCR) module, and a detection module. The amplification module is configured to receive an input sample, and defines a reaction volume. The amplification module includes a heater such that the amplification module can perform a polymerase chain reaction (PCR) on the input sample. The detection module is configured to receive an output from the amplification module and a reagent formulated to produce a signal that indicates a presence of a target amplicon within the input sample. The amplification module and the detection module are integrated within the housing.

The invention relates to the field of molecular diagnosis and tumor risk assessment, in particular to a marker combination and a kit for assessing the lymphatic metastasis risk of cervical cancer and application of the marker combination and the kit. The marker comprises a group of gene markers and a group of microbial markers, the gene markers comprise CARD9, MNX1AS2, MRAS, OLFML2A and RPS28, preferably, the gene markers further comprise at least one of CFL1P1 and GRASLND, and the microbial markers comprise microorganisms of the genus Dialister, the genus Catonella and the genus Campylobacter. The marker provided by the invention can be used for constructing an accurate risk assessment model, and can be used for developing a corresponding PCR (Polymerase Chain Reaction) kit, a mass spectrum or a chromatographic analysis system to realize metastasis risk prediction, curative effect assessment and new drug screening of cervical cancer patients.

The present invention relates to a probe set for an isothermal single reaction using a split T7 promoter and a use thereof. In the present invention, a design is made to introduce a split T7 promoter into a 3-way junction structure to produce a large quantity of fluorescent RNA aptamers at an isothermal temperature in the presence of a target molecule, and a nucleic acid biomarker can be detected rapidly and conveniently with only one enzyme in one pot. The probe set allows for various applications through high-sensitivity detection of multiple nucleic acid biomarkers and detection in which analysis is performed without an additional nucleic acid extraction process. In one pot, multiplex analysis can be conducted and molecular diagnosis can be made of various entities including viruses and pathogens.

The invention relates to a unified system for the extraction and purification of biomolecules using a novel Cloudy-Precipitated (CP) Buffer and an integrated extraction device. The CP Solution remains cloudy even when heated and enables single- or multi-step workflows for isolating nucleic acids without requiring multiple buffers or organic solvents. It contains optimized concentrations of detergents, chaotropic agents, salts, and adsorbents to efficiently lyse cells and minimize processing steps. The associated device incorporates a heating and filtration system that allows separation of target molecules from inhibitors or impurities based on molecular weight. It can operate as a single- or double-step configuration with various filter membrane options. This system reduces time, labor, and environmental impact while enhancing sample quality for molecular diagnostics, research, and therapeutic applications.

The utility model discloses a multifunctional transfer device and a workstation, and relates to the technical field of molecular diagnosis. The multifunctional transfer device comprises a mounting frame, a liquid transfer part and a clamping transfer part. Wherein the liquid transferring component comprises a liquid transferring power assembly movably arranged on the mounting frame, and the liquid transferring component can move in the first linear direction through the liquid transferring power assembly to generate a liquid suction force or a liquid repelling force; the clamping transfer part comprises a plurality of clamping hands and a clamping hand driving motor, and the clamping hands are rotatably arranged on the mounting frame and are in transmission connection with the clamping hand driving motor; the liquid transfer part and the clamping hand driving motor are arranged side by side in the second linear direction perpendicular to the first linear direction; the liquid transfer part is arranged between the at least two clamping hands in a third linear direction perpendicular to the first linear direction. Therefore, the device has the advantages that the overall structure is compact, and the application range is wide.

The utility model relates to the technical field of gene detection, and particularly discloses a molecular extraction mechanism and molecular diagnosis pretreatment equipment, in the molecular extraction mechanism, a rack is provided with an extraction station capable of containing a test tube; the flapping driving assembly is arranged on the rack; a flapping piece of the flapping assembly is provided with a containing groove which extends in the Z direction and is provided with an upward opening. The flapping piece is arranged at the output end of the flapping driving assembly and can synchronously move along with the output end of the flapping driving assembly, so that the flapping part of the flapping piece flaps a sample in the test tube; the extraction driving assembly is arranged on the rack; the extraction assembly comprises a magnetic bar, and the magnetic bar is in transmission connection with the output end of the extraction driving assembly and can move into the containing groove or move out of the containing groove along with the output end of the extraction driving assembly in the Z direction. According to the arrangement, the nucleic acid extraction efficiency is improved, the possibility of being polluted is also reduced, meanwhile, the magnetic bar is prevented from being cleaned, waste generated by cleaning is reduced, and the cost is saved.

Described herein is a singleplex RT-LAMP-based tests using modified primer sets. Contrived whole blood samples containing HIV-1 or HCV virions were diluted in equal parts water and loaded directly into optimized RT-LAMP master mixes. To mitigate cold-chain storage dependence, RT-LAMP reactions were performed using a lyophilized master mix. The reactions were heated for, for example 30 minutes using a hand-held, battery-powered heating device for simultaneous virion lysis and amplification.

This invention provides a molecular diagnostic card sample introduction system, comprising a transport vessel, a sample holder, a sample tube, a molecular diagnostic card, a vacuum chamber, and a hot gun. The sample tube and the molecular diagnostic card are placed inside the sample holder, which is placed inside the transport vessel. The transport vessel transports the sample holder to the vacuum chamber. The molecular diagnostic card includes a first aspiration port, a second aspiration port, a third aspiration port, and a molecular diagnostic card cavity. The first, second, and third aspiration ports are respectively connected to the molecular diagnostic card cavity. The molecular diagnostic card also includes a non-deformable card body, and the molecular diagnostic card cavity is placed inside the non-deformable card body. The hot gun is movable to the first, second, and third aspiration ports. This system solves the technical problem of contamination during sample introduction and achieves full automation.

The invention relates to the technical field of molecular diagnosis and graphic processing, in particular to an electronic microarray chip dot matrix negative and positive judgment method based on an ISFET sensor. A chip hole site corresponds to an ISFET sensor, and after a hole bottom specific nucleic acid probe and a target sequence are hybridized and extended, the voltage of the sensor is changed. The method specifically comprises the following steps: data preprocessing: filtering median values of multi-frame electric signals of a hole site and taking a mean value; the dot matrix identification comprises the steps of threshold demarcation, Canny edge detection, circular Hough transform, optimal circle screening by Kdtree, array numbering and abnormal deletion processing to position a dot matrix; and calculating a result, extracting a signal difference value of the D1 stage and the D4 stage, evaluating numerical values of the positive quality control array and the to-be-detected sample array through a numerical value of the negative quality control array, and judging a final calculation result. According to the method, response changes are rapidly analyzed through image recognition, false detection and missing detection caused by numerical value differences in different arrays are reduced through multiple times of detection, and the detection accuracy is improved by selecting the most possible area through tickets.

The invention belongs to the technical field of biology, and relates to a bronchoalveolar lavage fluid (BALF) preserving fluid, a kit and a cytological test method. The preservation solution is composed of TCEP, N-acetylcysteine, EDTA.2Na, trehalose, Proclin300, methanol, sodium chloride and HEPES, and all the components have a synergistic effect to achieve sample viscosity removal, oxidation resistance, corrosion prevention, cell protection and pH stabilization. The preserving fluid is suitable for morphological observation and nucleic acid detection of BALF cells, and can stably preserve samples at room temperature and maintain completeness of cell membranes and clear morphological structure. The kit comprises two preparations which are mixed to form a working solution, and the working solution can be directly used for sample preservation on a sampling site. The cytological test method comprises the steps of sample collection, preservation, centrifugal slide preparation, Wright-Giemsa staining and microscopic observation. Experimental results show that preservation solutions of different formulas are compatible with a chromosome system, the cell morphology is kept stable within 3 days, the dyeing effect is good, and it is proved that the preservation system can remarkably improve the preservation stability and detection reliability of BALF samples and is suitable for cytology and molecular diagnosis application of lower respiratory diseases.

The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a reagent for detecting TREM2 in preparation of a diagnostic kit for chronic kidney disease osteoporosis. The invention finds that the TREM2 signal channel is closely related to the common pathological background of chronic kidney disease and osteoporosis. Therefore, the TREM2 can be used as an expression characteristic and a molecular diagnosis marker in the chronic kidney disease-related osteoporosis, so that the chronic kidney disease-related osteoporosis can be subjected to early diagnosis. On the basis, the invention provides application of the TREM2 detection reagent in preparation of the chronic kidney disease osteoporosis diagnosis kit, and the application prospect is good.

The invention discloses a chirality-like crRNA mediated CRISPR (clustered regularly interspaced short palindromic repeats) / Cas12a one-pot detection method, and belongs to the technical field of molecular detection. The chirality-like crRNA can be used as a'delay switch 'of Cas12a activity activation, and a guided Cas12a system shows a unique delayed cutting characteristic. By means of the unique characteristics, the one-pot sensing strategy solves the problem that a Cas12a cutting system and a nucleic acid amplification system in a single reaction container are not compatible, and compared with a traditional crRNA mediated one-pot method reaction, the sensitivity is improved by 1000 times. In addition, a portable diagnostic (DFTFD) platform is constructed for on-site detection. The CRISPR / Cas12a molecular marker has great potential in promotion of application of CRISPR / Cas12a in basic research and promotion of development of a next-generation field detection molecular diagnosis platform.

The invention relates to the technical field of molecular diagnosis and virology detection, and discloses a method for rapidly detecting foot-and-mouth disease viruses based on a CRISPR / Cas12a system and an RPA amplification technology, which breaks through the dependence limitation of a traditional detection method on a precise instrument by integrating a dual technical path of RPA isothermal amplification and CRISPR / Cas12a fluorescence detection, and improves the detection accuracy of the foot-and-mouth disease viruses. The whole detection process can be completed under the basic equipment condition, the feasibility of on-site rapid screening is improved, meanwhile, specific recognition is conducted on target genes through the trans-cleavage characteristic of Cas12a, the misjudgment risk caused by cross reaction between serotypes is avoided, the accuracy and reliability of the detection result are guaranteed, and the detection efficiency is improved. By optimizing a Cas12a-crRNA compound pre-incubation mechanism and reaction system dynamic balance control, the interference influence of ambient temperature fluctuation on enzyme activity is overcome, so that the detection system can still maintain stable cutting efficiency under complex field conditions.